| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-06 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.15 | 3e-06 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.17 | 0.0001 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |